Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Replicor Inc. logo — 292 million people have chronic hepatitis B. We're developin...

Replicor Inc.

292 million people have chronic hepatitis B. We're developing the cure.

Canada Montreal, Canada 6 employees Biotechnology, Health Care

General Information

Company Name Replicor Inc.
Location Canada Montreal, Canada
Employees 6
Industries Biotechnology, Health Care
Social

Get notified when Replicor Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Replicor Inc.

Replicor Inc. is a Canadian biotechnology company dedicated to developing a cure for chronic hepatitis B (HBV) and delta (HDV) infections. Their innovative nucleic acid polymer (NAP) technology directly targets the immunosuppressive protein (HBsAg) responsible for chronic HBV infection and liver disease. Their lead clinical NAP drug product, REP 2139-Mg, has shown promising results in restoring immune control of HBV infection in 78% of patients and eliminating HDV infection in 74% of patients. What's particularly noteworthy is that these effects persist without any therapy, allowing the liver to heal. Moreover, their REP 2139-Mg based combination therapy is poised to revolutionize the treatment of chronic HBV and HDV infections and aligns with the WHO's goal of eliminating viral hepatitis by 2030. With 292 million people suffering from chronic hepatitis B, Replicor's work could potentially have a significant global impact.

Taxonomy: clinical-stage company, hepatitis B, HBV treatment, antiviral therapy, NAP technology, chronic infection, liver disease, clinical data, viral hepatitis, drug development, nucleic acid-based polymers, immune control, viral infections, innovative treatment

No funding data available for Replicor Inc. yet.

Get notified when Replicor Inc. raises funding

Replicor Inc. Alternatives & Competitors

Replicor Inc. vs
Aligos Therapeutics
Aligos Therapeutics United States

Improving patient outcomes through best-in-class therapies for liver and viral diseases

Unknown
97 employees
Biotechnology
Compare Replicor Inc. vs Aligos Therapeutics
Replicor Inc. vs
Assembly Biosciences, Inc.
Assembly Biosciences, Inc. United States

Passionate about making a profound impact on patients’ lives

IPO
101 employees
Biotechnology
Replicor Inc. vs
Hepion Pharmaceuticals
Hepion Pharmaceuticals United States

Hepion Pharmaceuticals, Inc. is not affiliated in any way with Wire™ or Wire Swiss GmbH in any capac...

Post Ipo Debt
7 employees
Biotechnology, Life Sciences

FAQ About Replicor Inc.

292 million people have chronic hepatitis B. We're developing the cure.
Replicor Inc. is headquartered in Montreal, Canada.
Replicor Inc. operates in the following industries: Biotechnology, Health Care.
Replicor Inc. has approximately 6 employees.
Top alternatives and competitors to Replicor Inc. include Aligos Therapeutics, Assembly Biosciences, Inc., Hepion Pharmaceuticals, Idenix Pharmaceuticals, Vital Therapies. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Replicor Inc. and Aligos Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Replicor Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes